ALXN stock news

— Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported earnings of $2.71 per share in the fourth-quarter 2019, vs. $2.60 per share expected. — Total revenue rose… Read more
Alexion Pharmaceuticals (NASDAQ:ALXN): Q4 Non-GAAP EPS of $2.71 beats by $0.10; GAAP EPS of $4.00 beats by $1.91. Revenue of $1.38B (+22.1% Y/Y) beats by $ Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 27) 10X Genomics Inc (NASDAQ: TXG ) Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN )(announced early termination of waiting period for its proposed acquisition by Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN )) Cidara Therapeutics Inc (NASDAQ: CDTX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI )(saw a coronavirus-induced rally ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY )(reacted to its Q3 results) Inovio Pharmaceuticals Inc (NASDAQ: INO )(announced Nevro Corp (NYSE: NVRO ) Oyster Point Pharma Inc (NASDAQ: OYST ) Quest Diagnostics Inc (NYSE: DGX ) Rapt Therapeutics Inc (NASDAQ: RAPT ) SI-Bone Inc (NASDAQ: SIBN ) Vaccinex Inc (NASDAQ: VCNX ) Vir Biotechnology Inc (NASDAQ: VIR ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. 27) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Autolus Therapeutics Ltd – ADR (NASDAQ: AUTL ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Avanos Medical Inc (NYSE: AVNS ) Blueprint Medicines Corp (NASDAQ: BPMC ) Correvio Pharma Corp (NASDAQ: CORV ) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) Heat Biologics Inc (NASDAQ: HTBX ) HTG Molecular Diagnostics Inc (NASDAQ: HTGM ) Kura Oncology Inc (NASDAQ: KURA ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) MediciNova, Inc. Read more
The Zacks Analyst Blog Highlights: Lear, SEI Investments, Alexion Pharmaceuticals and Apartment Investment and Management Read more
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has updated the time of its fourth quarter and full year 2019 earnings call on January 30, 2020 to 7:30 a.m. Eastern Time. The call had previously been scheduled for 8:00 a.m. ET. All other aspects of the call remain unchanged. The Company will report its financial results for the fourth quarter and full year ended December 31, 2019 before the US financial markets open on January 30, 2020. To participa Read more
Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis. Read more
APVO436 is the Latest Investigational AML Therapeutic to be Selected for Participation in the Study; Aptevo Joins Industry Leaders, Bristol-Myers Squib (formerly Celgene) Alexion Pharmaceuticals, Gilead … Read more
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 38th Annual J.P Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 14th, 2019 at 7:30 a.m, PT. A breakout question and answer session will immediately follow the formal presentation. An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.alexion.com. An archived version of the remarks will also be available through t Read more
Alexion's (ALXN) growth prospects look strong for 2020 as Soliris maintains momentum and Ultomiris gains further traction. Read more
REUTERS: Alexion Pharmaceuticals Inc said on Friday its board of directors had unanimously rejected hedge fund Elliott Management's push for a "proactive sale" process of the entire company because it would not be in the best interest of shareholders. Alexion has been fighting to maintain its … Read more
Alexion Pharmaceuticals Inc said on Friday its board of directors had unanimously decided against hedge fund Elliott Management's push for a "proactive sale" process, saying it would not be in the best interest of shareholders. For years, Elliott Management, which has built a stake in Read more
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the 2019 Evercore ISI HealthCONx in Boston, MA on Tuesday, December 3rd, 2019 at 8:45 a.m. ET. An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.alexion.com. An archived version of the remarks will also be available through the Company’s website for a limited time following the conference. [ALXN-G] Read more
iCo Therapeutics Inc. announced today that the purchase of the assets of Immune Pharmaceuticals , including the sublicense of iCo-008, by Alexion Pharmaceuticals, Inc. has received all requisite… | November 25, 2019 Read more
Charts of the Boston-based Alexion Pharmaceuticals to do not provide a compelling case to buy the stock….ALXN Read more
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. Read more

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

Proudly Made At

ROCKIT